Sixth Peoples Hospital of Hebei Province

Baoding, China

Sixth Peoples Hospital of Hebei Province

Baoding, China

Time filter

Source Type

Li Y.-Y.,Sixth Peoples Hospital of Hebei Province | Zhang Y.-S.,Sixth Peoples Hospital of Hebei Province | Wang J.,Sixth Peoples Hospital of Hebei Province | Li K.-Q.,Sixth Peoples Hospital of Hebei Province | Wang H.-Y.,Sixth Peoples Hospital of Hebei Province
Acta Academiae Medicinae Sinicae | Year: 2016

Objective: To systematically evaluate the efficacy of clozapine combined with other antipsychotic drugs in the treatment of refractory schizophrenia. Methods: We searched Medline, EMBASE, and China Biology Medicine databases in both English and Chinese for randomized controlled trials, quasi-randomization controlled trials, and clinical controlled trials concerning the combinations of clozapine with other antipsychotic drugs for refractory schizophrenia. Quality assessment and data extraction were conducted with the Cochrane collaboration' s RevMan 5. 3 software. Results: Totally 47 trials met the inclusion criteria, in which clozapine was combined with risperidone, aripiprazole, sulpiride, ziprasidone, modified electroconvulsive therapy, valproate, or lithium carbonate, respectively. Analysis showed that most combination strategies were superior to clozapoine alone (P <0. 05), except for the combination with lithium carbonate (8 weeks; RR = 1. 27, 95% CI =0. 82-1. 97, P = 0. 28; 12 weeks: RR = 1. 53, 95% CI = 0.45-5. 13, P = 0. 49). Conclusion: Reasonable combination of clozapine with other drugs may improve the therapeutic effectiveness and reduce adverse reactions and thus can be effectively used for treating refractory schizophrenia.


Wang X.-J.,Tangshan Workers Hospital | Li L.-Z.,Peking University | Xiao W.-D.,Hubei General Hospital | Du B.,Sixth Peoples Hospital of Hebei Province | Mi W.-F.,Peking University
Journal of Clinical Rehabilitative Tissue Engineering Research | Year: 2010

BACKGROUND: As the first long-acting atypical antipsychotics, the therapeutic effect and safety of risperidone microsphere have been proved. However, it may lead to serious pain due to the deep intramuscular injection. OBJECTIVE: To evaluate the pain levels by 12-week injection of risperidone microsphere and to explore the relationship among dose and times of injection of risperidone microsphere and pain levels. METHODS: A total of 57 patients diagnosed as schizoprenia by DSM-IV, aged 18-65 years, were selected and injected risperidone microsphere once every 2 weeks with doses of 25, 37.5 and 50 mg. The pain levels were evaluated using 100 mm visual analogue scale during injection and at the injected sites. The effects of injected dose, injected frequency and injected sites on the pain were analyzed by the nurse questionnaire. RESULTS AND CONCLUSION: The pain levels among the different doses groups had no notable differences (F = 1.35, P > 0.05), which demonstrated that the pain had no relationship with injected dose. However, the pain level of injected sites had correlation to injected doses. The pain level of the 50 mg group was greater than that of the 37.5 and 25 mg groups. Accordingly, patients who treated by high dose of risperidone microsphere should be intervened by nurses.


Wang X.,Peking University | Xia M.,Beijing Normal University | Lai Y.,Peking University | Dai Z.,Beijing Normal University | And 13 more authors.
Schizophrenia Research | Year: 2014

Objective: The pathophysiology of chronic schizophrenia may reflect long term brain changes related to the disorder. The effect of chronicity on intrinsic functional connectivity patterns in schizophrenia without the potentially confounding effect of antipsychotic medications, however, remains largely unknown. Method: We collected resting-state fMRI data in 21 minimally treated chronic schizophrenia patients and 20 healthy controls. We computed regional functional connectivity strength for each voxel in the brain, and further divided regional functional connectivity strength into short-range regional functional connectivity strength and long-range regional functional connectivity strength. General linear models were used to detect between-group differences in these regional functional connectivity strength metrics and to further systematically investigate the relationship between these differences and clinical/behavioral variables in the patients. Results: Compared to healthy controls, the minimally treated chronic schizophrenia patients showed an overall reduced regional functional connectivity strength especially in bilateral sensorimotor cortex, right lateral prefrontal cortex, left insula and right lingual gyrus, and these regional functional connectivity strength decreases mainly resulted from disruption of short-range regional functional connectivity strength. The minimally treated chronic schizophrenia patients also showed reduced long-range regional functional connectivity strength in the bilateral posterior cingulate cortex/precuneus, and increased long-range regional functional connectivity strength in the right lateral prefrontal cortex and lingual gyrus. Notably, disrupted short-range regional functional connectivity strength mainly correlated with duration of illness and negative symptoms, whereas disrupted long-range regional functional connectivity strength correlated with neurocognitive performance. All of the results were corrected using Monte-Carlo simulation. Conclusions: This exploratory study demonstrates a disruption of intrinsic functional connectivity without long-term exposure to antipsychotic medications in chronic schizophrenia. Furthermore, this disruption was connection-distance dependent, thus raising the possibility for differential neural pathways in neurocognitive impairment and psychiatric symptoms in schizophrenia. © 2014 Elsevier B.V.


Wang Y.,Anhui Medical University | Liu P.,Anhui Medical University | Feng X.-L.,Anhui Medical University | Wang B.-Y.,Anhui Medical University | And 12 more authors.
Neuropsychobiology | Year: 2010

Background: Preclinical studies have shown that brain-derived neurotrophic factor (BDNF) may be involved in antidepressant action, and the BDNF gene has been suggested to be involved in the pharmacological treatment of major depressive disorder (MDD). In this study, the relationship between BDNF Val66Met polymorphism (Single Nucleotide Polymorphism Database ID: rs6265) and severity of depression, efficacy of fluoxetine and its side effects was tested in Chinese patients with MDD. Methods: Patients with MDD took the oral selective serotonin reuptake inhibitor (SSRI) fluoxetine (20 mg/day) for 6 weeks. Its clinical efficacy and side effects were measured by the 17-item Hamilton Rating Scale for Depression and the Treatment-Emergent Symptoms Scale (TESS), respectively. The patients were genotyped for Val66Met polymorphism of the BDNF gene. Results: In the multivariate regression analysis, there was no significant association between severity of depression and BDNF Val66Met polymorphism. There was no association between efficacy of fluoxetine and BDNF Val66Met polymorphism, but there was a marginal positive suggestion that heterozygous patients tended to have a better remission with fluoxetine in comparison with homozygous analogs. Insomnia and decreased sexual desire, side effects of fluoxetine, may have an association with the BDNF Val66Met polymorphism, and Met allele carriers showed a lower incidence of these side effects. Conclusions: These results indicate that there was a lack of association between severity of depression and BDNF Val66Met polymorphism in Chinese patients with MDD. The BDNF Val66Met polymorphism may play a major role in the efficacy and side effects of SSRI (fluoxetine) in Chinese patients with MDD. © 2009 S. Karger AG, Basel.


Zou Y.-F.,Anhui Medical University | Wang Y.,Anhui Medical University | Liu P.,Anhui Medical University | Feng X.-L.,Anhui Medical University | And 14 more authors.
Human Psychopharmacology | Year: 2010

Objective: To explore the association of brain-derived neurotrophic-factor (BDNF) Val66Met polymorphism with both baseline health related quality of life (HRQOL) scores and improvement in HRQOL scores in Chinese major depressive patients treated with fluoxetine. Methods: Patientswith major depressive disorder (MDD) took fluoxetine (20 mg/day) for 6 weeks. TheHRQOL wasmeasuredwith theMedical Outcomes Study Short Form-36 (SF-36) at baseline and at 6th week. Patients were genotyped for Val66Met polymorphism of BDNF gene. Results: There was a significant association between social function (SF) and BDNF Val66Met polymorphism, and patients with Met/Met genotype had better SF (compared with Val/Val P = 0.004; compared with Val/Met P = 0.005). A significant association was found between improvement in SF and BDNF Val66Met polymorphism, and patients with Met/Met genotype had poorer improvement in SF (compared with Val/Val P = 0.010; compared with Val/Met P = 0.001). Similar association was found between improvement in mental component summary (MCS) and BDNF Val66Met polymorphism, and patients with Met/Met genotype had poorer improvement in MCS (compared with Val/ Val P = 0.066; compared with Val/Met P = 0.006). Conclusions: These results indicate that there may be association between BDNF Val66Met polymorphism and both baseline HRQOL (SF) scores and improvement in HRQOL (SF, MCS) scores in Chinese major depressive patients treated with fluoxetine. Copyright © 2010 John Wiley & Sons, Ltd.


Li Y.-Y.,Sixth Peoples Hospital of Hebei Province | Wang H.-Y.,Sixth Peoples Hospital of Hebei Province | Cui L.-J.,Sixth Peoples Hospital of Hebei Province | Sang W.-H.,Sixth Peoples Hospital of Hebei Province | And 2 more authors.
Journal of Dalian Medical University | Year: 2014

Objective: To systematicly evaluate the efficacy of Brisking treating Schizophrenia, providing reference for the reasonable use of this drug.Methods: We searched CBM, CNKI for randomized controlled trials (RCTs) and quasi - randomization controlled trials. Quality assessment and data extraction were conducted by two reviewers independently. Meta - analyses were conducted with the Cochrane Collaboration' s RevMan 5. 0 software.Results: Seven trials met the inclusion criteria.Results: Showed: The effects for Schizophrenia are no significant difference between brisking and other non - classical antipsychotics [RR = 1.01,95% CI (0.93,1. 10), P= 0.77]. The effects for Schizophrenia are also no significant difference between Brisking and classical - antipsychotics [RR = 1.02,95% CI(0. 95,1. 09), P = 0. 68].Conclusion: No significant differences were observed in the effects between brisking and other antipsychotics for Schizophrenia, We could expand its use, especially for incipient patients and elderly patients.


Zhao A.,Hebei University | Zhang D.,Hebei University | Xu X.,Sixth Peoples Hospital of Hebei Province
Applied Mechanics and Materials | Year: 2010

The text of the video can provide important information for video description and retrieval. First,the paper adopts Maximum Gradient algorithm which is based on the Sobel Gradient operator to detect the edge of the text. Second, with regards to the rich information of the edge of text, variance projection is employed to detect text zones and to filtrate false text zones by calculating the Regional Density. Finally, Image Morphology is employed to treat the edge of the text. It is to get position and color information of pixels of original image and extract text from complex background. A large number of experiments to prove that the algorithm is very effective. © (2010) Trans Tech Publications.

Loading Sixth Peoples Hospital of Hebei Province collaborators
Loading Sixth Peoples Hospital of Hebei Province collaborators